MAPK1 and breast carcinoma: For instance, ERK1 and ERK2 are overexpressed in 26%–45% of all molecular subtypes of breast cancer [21], which implies that the Ras/ERK pathway is more frequently activated by other mechanisms in breast cancer such as genomic or epigenetic variation of other pathway components [9, 11, 17].